Scientists reveal how bacteria switch direction through a microscopic tug-of-war inside their motors, driven by energy and ...

Scientists have uncovered a new explanation for how swimming bacteria change direction, providing fresh insight into one of ...

Third Person Shooter How to complete Snap and Salvage in Arc Raiders Third Person Shooter Arc Raiders roadmap: All upcoming content and updates Third Person Shooter This is where I found the Anvil ...

The Equilibrium Dungeon, the premiere endgame activity in Destiny 2: Renegades, asks those who challenge it to overcome long odds and the burgeoning threat of a new set of Dredgens. Completing it ...

Jake Fillery is an Evergreen Editor for Game Rant who has been writing lists, guides, and reviews since 2022. With thousands of engaging articles and guides, Jake loves conversations surrounding all ...

ORLANDO, Fla.—The leader of Gilead Sciences' Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger ...

Video of brutal Seattle attack on elderly woman sparks anger Johnny Carson book exposes 'Tonight Show' ban list featuring Jay Leno, Ellen DeGeneres Hegseth’s shakeup could redraw military map 40 ...

Splinter Cell: Deathwatch brings Sam Fisher out of retirement for one final mission, but maybe it shouldn't have bothered. While it occasionally sparks into life in the final act (with Liev Schreiber ...

Erick Massoto is a Brazilian writer who's always loved film and TV and loves finding connections between them. That's why he supports double features, especially if they are of a modern film paired ...

CEL-SCI Corporation (NYSE:CVM) shares tumbled 38.19% in after-hours trading to $8.06 on Tuesday following the cancer immunotherapy company’s announcement of a $10 million public offering priced below ...